IJCEM Copyright © 2008-All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711
Int J Clin Exp Med 2011;4(2):148-156

Original Article
Application of hazard models for patients with breast cancer in Cuba

Anet García Alfonso, Néstor Arcia Montes de Oca

National Center Coordinators of Clinical Trials; National Statistics Office, Cuba.

Received February 15, 2010; accepted March 29, 2011; Epub April 6, 2011; published May 15, 2011

Abstract: There has been a rapid development in hazard models and survival analysis in the last decade. This article aims to assess
the overall survival time of breast cancer in Cuba, as well as to determine plausible factors that may have a significant impact in the
survival time.  The data are obtained from the National Cancer Register of Cuba. The data set used in this study relates to 6381
patients diagnosed with breast cancer between January 2000 and December 2002. Follow-up data are available until the end of
December 2007, by which time 2167 (33.9%) had died and 4214 (66.1%) were still alive. The adequacy of six parametric models is
assessed by using their Akaike information criterion values. Five of the six parametric models (Exponential, Weibull, Log-logistic,
Lognormal, and Generalized Gamma) are parameterized by using the accelerated failure-time metric, and the Gompertz model is
parameterized by using the proportional hazard metric. The main result in terms of survival is found for the different categories of the
clinical stage covariate. The survival time among patients who have been diagnosed at early stage of breast cancer is about 60%
higher than the one among patients diagnosed at more advanced stage of the disease. Differences among provinces have not been
found. The age is another significant factor, but there is no important difference between patient ages. (IJCEM1102003).

Keywords: Survival analysis, Akaike information criterion, accelerated failure-time metric, proportional hazard metric

Full Text  PDF

Address all correspondence to:
Anet García Alfonso, PhD
National Center Coordinators of Clinical Trials
Havana, Cuba.